Analyst Ratings For NASDAQ:ESPR – Esperion Therapeutics (NASDAQ:ESPR)
Today, UBS reiterated its Buy rating on NASDAQ:ESPR – Esperion Therapeutics (NASDAQ:ESPR) with a price target of $90.00 ➝ $75.00.
Some recent analyst ratings include
- 5/16/2018-UBS Reiterated Rating of Buy.
- 5/3/2018-JPMorgan Chase was Downgraded by analysts at JPMorgan Chase from a “Neutral ➝ Underweight” rating to a “” rating. They now have a $100.54 ➝ $41.00 price target on the stock.
- 5/2/2018-Bank of America Reiterated Rating of Buy ➝ Underperform.
Recent Insider Trading Activity For NASDAQ:ESPR – Esperion Therapeutics (NASDAQ:ESPR)
NASDAQ:ESPR – Esperion Therapeutics (NASDAQ:ESPR) has insider ownership of 14.50% and institutional ownership of 91.38%.
- On 3/29/2018 Roger S Newton, Director, sold 25,000 with an average share price of $72.37 per share and the total transaction amounting to $1,809,250.00.
- On 1/25/2018 Nicole Vitullo, Director, sold 11,674 with an average share price of $71.79 per share and the total transaction amounting to $838,076.46.
- On 12/6/2017 Nicole Vitullo, Director, sold 9,326 with an average share price of $53.85 per share and the total transaction amounting to $502,205.10.
- On 3/22/2017 Dov A Md Goldstein, Director, sold 800,000 with an average share price of $41.66 per share and the total transaction amounting to $33,328,000.00.
- On 3/21/2017 Gilbert S Omenn, Director, bought 1,000 with an average share price of $42.26 per share and the total transaction amounting to $42,260.00.
- On 11/1/2016 Narendra D Lalwani, COO, bought 5,000 with an average share price of $9.93 per share and the total transaction amounting to $49,650.00.
- On 7/6/2016 Mark E Mcgovern, Director, bought 5,000 with an average share price of $10.00 per share and the total transaction amounting to $50,000.00.
Recent Trading Activity for NASDAQ:ESPR – Esperion Therapeutics (NASDAQ:ESPR)
Shares of NASDAQ:ESPR – Esperion Therapeutics closed the previous trading session at 41.46 up +0.46 1.11% with 70553 shares trading hands.